In 2023, we expect to invest about 5% of revenue in property, plant and equipment. About 41% of the capital expenditure planned will be invested at Fresenius Medical Care, about 26% at Fresenius Kabi, and around 27% at Fresenius Helios.

At Fresenius Medical Care, investments will mainly be made in expanding production capacities, optimizing production costs, and setting up new dialysisDialysisForm ​of ​renal ​replacement ​therapy ​where ​a ​semipermeable ​membrane ​– ​in ​peritoneal ​dialysis ​the ​peritoneum ​of ​the ​patient, ​in ​hemo­ ​dialysis ​the ​membrane ​of ​the ​dialyzer ​– ​is ​used ​to ​clean ​a ​patient’s ​blood. clinics.

Fresenius Kabi will mainly invest in the expansion and maintenance of its production sites and in the introduction of new production technologies.

Fresenius Helios will primarily invest in the construction and modernization of existing and newly acquired clinics and medical centers.

Fresenius Vamed is primarily investing in modernizing and equipping existing post-acute care facilities.

With a share of around 60%, Europe is the regional focus of investment in the planning period. Around 30% of the investments are planned for North America and around 10% for Asia-Pacific, Latin America, and Africa. About 30% of total funds will be invested in Germany.

For 2022, we assume return on invested capital (ROICROIC (Return on Invested Capital)Calculated ​by: ​(EBIT ​- ​taxes) ​/ ​Invested ​capital. ​ Invested ​capital ​= ​total ​assets ​+ ​accumulated ​amortization ​of ​goodwill ​- ​deferred ​tax ​assets ​- ​cash ​and ​cash ​equivalents ​- ​trade ​accounts ​payable ​- ​accruals ​(without ​pension ​accruals) ​- ​other ​liabilities ​not ​bearing ​interest.) to decline around one percentage point below the level of 2022 (2022: 5,1%).